This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by de Haas, S.L. Articles by van Gerven, J.M.A. Search for Related Content PubMed PubMed Citation Articles by de Haas, S.L. Articles by van Gerven, J.M.A. Social Bookmarking                         What's this?

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA_{A 2,3} subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers

Centre for Human Drug Research, Leiden, The Netherlands, ShaaS{at}chdr.nl

S.J. de Visser

Centre for Human Drug Research, Leiden, The Netherlands

J.P. van der Post

Centre for Human Drug Research, Leiden, The Netherlands

R.C. Schoemaker

r Centre for Human Drug Research, Leiden, The Netherlands

K. van Dyck

MSD (Europe) Inc., Brussels, Belgium

M.G. Murphy

MRL, Upper Gwynedd/West Point, PA, USA

M. de Smet

MSD (Europe) Inc., Brussels, Belgium

L.K. Vessey

MRL, Upper Gwynedd/West Point, PA, USA

R. Ramakrishnan

MRL, Upper Gwynedd/West Point, PA, USA

L. Xue

MRL, Upper Gwynedd/West Point, PA, USA

A.F. Cohen

Centre for Human Drug Research, Leiden, The Netherlands

J.M.A. van Gerven

Centre for Human Drug Research, Leiden, The Netherlands

The use of non-selective -aminobutyric acid (GABA) enhancers, such as benzodiazepines in the treatment of anxiety disorders is still widespread but hampered by unfavourable side effects. some of these may be associated with binding properties to certain subtypes of the GABA_A receptor that are unnecessary for therapeutic effects. MK-0343 was designed to be a less sedating anxiolytic, based on reduced efficacy at the 1 subtype and significant efficacy at 2 and 3 subtypes of the GABA_A receptor.

This paper is a double-blind, four-way cross-over (n = 12) study to investigate the effects of MK-0343 (0.25 and 0.75 mg) in comparison to placebo and an anxiolytic dose (2 mg) of the non-selective agonist lorazepam. Effects were measured by eye movements, body sway, Visual Analogue scales (VAs) and memory tests.

Lorazepam impaired saccadic peak velocity (sPV), VAs alertness scores, postural stability and memory and increased saccadic latency and

inaccuracy. MK-0343 0.75 mg was equipotent with lorazepam as indicated by sPV (-42.4 deg/s), saccadic latency (0.02 s) and VAs alertness scores (1.50 ln mm), while effects on memory and postural stability were smaller. MK-0343 0.25 mg only affected postural stability to a similar extent as MK-0343 0.75 mg.

The effect profile of MK-0343 0.75 mg is different from the full agonist lorazepam, which could reflect the selective actions of this compound. Although less effect on VAs alertness was expected, diminished effects on memory and postural stability were present. Clinical studies in anxiety patients should show whether this dose of MK-0343 is therapeutically effective with a different side-effect profile.

Key Words: MK-0343 • selective partial GABA agonist • memory • body sway • saccadic eye movements • sedation • benzodiazepines

Journal of Psychopharmacology, Vol. 22, No. 1, 24-32 (2008)
DOI: 10.1177/0269881107082108


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. R. Atack, D. F. Wong, T. D. Fryer, C. Ryan, S. Sanabria, Y. Zhou, R. F. Dannals, W.-s. Eng, R. E. Gibson, H. D. Burns, et al. Benzodiazepine Binding Site Occupancy by the Novel GABAA Receptor Subtype-Selective Drug 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in Rats, Primates, and Humans J. Pharmacol. Exp. Ther., January 1, 2010; 332(1): 17 - 25. [Abstract] [Full Text] [PDF]

				S. Wilson and D. Nutt Drug treatment of chronic insomnia -- dawn at the end of a long night? J Psychopharmacol, September 1, 2008; 22(7): 703 - 706. [PDF]